Form 4: Silexion CSO Reports Share Grant Amid Reverse Splits

Silexion Therapeutics' Chief Scientific and Development Officer, Mitchell Shirvan, reported the acquisition of 49,726 ordinary shares through an RSU grant, following two significant reverse share splits.

Summary

• Mitchell Shirvan, Chief Scientific Officer and Chief Development Officer of Silexion Therapeutics Corp (SLXN), reported changes in his beneficial ownership of the company's securities.
• Shirvan acquired 49,726 ordinary shares on February 20, 2026, through a grant of fully vested restricted share units (RSUs) which were immediately settled for underlying ordinary shares.
• The RSU grant was approved by Silexion Therapeutics' board of directors and had a transaction price of $0.
• Following this transaction, Shirvan beneficially owns a total of 50,707 ordinary shares.
• The reported share numbers reflect adjustments due to two reverse share splits: a 1-for-9 split effected on November 29, 2024, and a 1-for-15 split effected on July 29, 2025.
• Shirvan also holds 478 stock options to purchase ordinary shares with an exercise price of $907.71, which are set to expire on June 7, 2032; these holdings are included for informational purposes only, with no transactions reported in this filing.
• A Power of Attorney was granted by Mitchell Shirvan to Mirit Horenshtein Hadar, the Chief Financial Officer of Silexion Therapeutics Corp, on August 15, 2024.
• This power authorizes Hadar to prepare, execute, and submit Forms 3, 4, and 5 to the SEC on Shirvan's behalf, related to his capacity as an officer, director, or beneficial owner of more than 10% of a registered class of securities of the Company.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this filing with caution. While the RSU grant aligns executive interests, the preceding two reverse share splits suggest significant underlying challenges for the company's stock performance.

Positives

• The grant of 49,726 fully vested restricted share units (RSUs) to a key officer, Mitchell Shirvan, indicates continued alignment of management interests with shareholders.
• The RSU grant was approved by the Issuer's board of directors, suggesting internal confidence and strategic compensation.

Negatives

• Silexion Therapeutics Corp underwent two significant reverse share splits (1-for-9 on November 29, 2024, and 1-for-15 on July 29, 2025), which often indicate a declining share price and efforts to maintain listing requirements or improve per-share metrics, typically viewed negatively by the market.

Risks

• Reverse share splits can sometimes be perceived negatively by the market, potentially indicating underlying financial or operational challenges and may not address the root causes of a low share price.

Future Outlook

No explicit forward-looking statements or guidance are provided beyond the expiration date of stock options. The recent reverse share splits, while historical, will impact the company's future share structure and per-share metrics.

Management Comments

• The undersigned acknowledges that the foregoing attorney-in-fact, and his substitutes, in serving in such capacity at the request of the undersigned, is not assuming (nor is the Company assuming) any of the undersigned's responsibilities to comply with Section 16 of the Exchange Act.

Industry Context

StockSavvy.ai notes that insider share grants, particularly fully vested RSUs, are a common form of executive compensation designed to align management incentives with shareholder value. However, the context of two recent reverse stock splits suggests the company may be facing challenges, as such actions are often taken to boost share price per share and meet listing requirements, which can be a red flag for investors in the biotechnology sector.

Comparison to Industry Standards

• The grant of fully vested RSUs to a key executive is a standard practice in the biotechnology and pharmaceutical sectors for executive compensation, similar to grants seen at companies like Moderna or Pfizer, aiming to retain talent and align interests.
• However, the occurrence of two reverse share splits (1-for-9 and 1-for-15) within a year is a significant event that deviates from the norm for healthy, growing companies in the industry. For instance, while companies like Sorrento Therapeutics have executed reverse splits due to low share prices, two such actions in quick succession often signal severe stock price depreciation and potential delisting risks, unlike stable industry leaders.

Corporate Governance

Related Party Transactions

• Grant of 49,726 fully vested restricted share units (RSUs) to Mitchell Shirvan, CSO and CDO, which were immediately settled for ordinary shares, representing a form of executive compensation.

Stakeholder Impact

• Shareholders: The reverse share splits significantly reduce the number of outstanding shares, potentially increasing the per-share price but not necessarily the overall market capitalization. The RSU grant aligns executive interests with shareholder value.
• Management/Executives: Mitchell Shirvan's compensation includes a significant RSU grant, aligning his financial interests with the company's performance. The Power of Attorney simplifies his SEC reporting obligations.

Next Steps

• Mirit Horenshtein Hadar, as attorney-in-fact, will continue to prepare and file Forms 3, 4, and 5 on behalf of Mitchell Shirvan as required by Section 16(a) of the Exchange Act.

Key Dates

Recommendation

While the RSU grant to a key executive aligns management's interests with shareholders, the company's recent history of two significant reverse share splits (1-for-9 and 1-for-15) within a year raises concerns about its underlying financial health and stock performance. Investors should hold and monitor for further operational and financial updates to assess the long-term viability and growth prospects.

Keywords

Silexion Therapeutics, SLXN, Form 4, SEC filing, beneficial ownership, RSU, restricted share units, stock options, reverse share split, corporate governance, insider transaction, executive compensation